Study patients
. | . | Prior lines of CHT . | . | . | Disease status at transplantation . | . | ||
|---|---|---|---|---|---|---|---|---|
| Characteristics . | No. of patients . | Median . | Range . | Patients receiving prior RT . | CR . | Presence of disease . | ||
| Hodgkin disease | 17 | 3 | 1-4 | 12 | 7 | 10 | ||
| Non-Hodgkin lymphoma* | 41 | 3 | 1-5 | 20 | 23 | 18 | ||
| Multiple myeloma† | 7 | 3 | 0-5 | 4 | 0 | 7 | ||
| Acute leukemia‡ | 21 | 2 | 1-3 | 0 | — | — | ||
| AML | 18 | — | — | — | 17 | 1 | ||
| ALL | 3 | — | — | — | 2 | 1 | ||
. | . | Prior lines of CHT . | . | . | Disease status at transplantation . | . | ||
|---|---|---|---|---|---|---|---|---|
| Characteristics . | No. of patients . | Median . | Range . | Patients receiving prior RT . | CR . | Presence of disease . | ||
| Hodgkin disease | 17 | 3 | 1-4 | 12 | 7 | 10 | ||
| Non-Hodgkin lymphoma* | 41 | 3 | 1-5 | 20 | 23 | 18 | ||
| Multiple myeloma† | 7 | 3 | 0-5 | 4 | 0 | 7 | ||
| Acute leukemia‡ | 21 | 2 | 1-3 | 0 | — | — | ||
| AML | 18 | — | — | — | 17 | 1 | ||
| ALL | 3 | — | — | — | 2 | 1 | ||
CHT indicates chemotherapy; RT, radiotherapy; CR, complete remission; and —, not applicable.
Indolent lymphoma (n = 10); aggressive lymphoma (n = 31).
All patients had stage III A disease according to Durie and Salmon classification.
In first CR were 14 AML patients. For further details, see “Results.”